India Globalization Capital

India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders.

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series. In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss therapies.

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

- Company Expands Phase 2 trial to Canada - POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, Canada, as part of the Company's ongoing Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia. Agitation affects between 40-80% of Alzheimer's patients and is a major driver of long-term hospitalization, increased mortality, and higher use of medication.

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

POTOMAC, MD / ACCESSWIRE / October 3, 2024 / IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database. IGC Pharma, Inc. The PREPARE Challenge is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institutes of Health ("NIH").

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment.

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease.

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease.

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports First Quarter Fiscal 2025 Results.

IGC Pharma Reports First Quarter Fiscal 2025 Results

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target.

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile.

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease.

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets.

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Publishes Study in European Society of Medicine.

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1.

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Attend BIO International Convention 2024.

IGC Pharma to Attend BIO International Convention 2024

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two.

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Adds Advisor in Artificial Intelligence.

IGC Pharma Adds Advisor in Artificial Intelligence

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock.

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation.

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024.

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma (IGC)- Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline.

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Ascendiant Coverage.

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Third Quarter Fiscal 2024 Results.

IGC Pharma Reports Third Quarter Fiscal 2024 Results

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--TGR-63 Reduces Agitation in Alzheimer's Mouse Model.

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Breakthrough - Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's.

News for India Globalization Capital Stock (IGC)